Shandong Sinobioway Biomedicine Co Ltd (002581) - Total Liabilities
Based on the latest financial reports, Shandong Sinobioway Biomedicine Co Ltd (002581) has total liabilities worth CN¥221.51 Million CNY (≈ $32.41 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Shandong Sinobioway Biomedicine Co Ltd (002581) cash flow conversion to assess how effectively this company generates cash.
Shandong Sinobioway Biomedicine Co Ltd - Total Liabilities Trend (2007–2024)
This chart illustrates how Shandong Sinobioway Biomedicine Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Shandong Sinobioway Biomedicine Co Ltd to evaluate the company's liquid asset resilience ratio.
Shandong Sinobioway Biomedicine Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shandong Sinobioway Biomedicine Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Song Da Urban & Industrial Zone Investment and Development JSC
VN:SJS
|
Vietnam | ₫4.43 Trillion |
|
Intellian Technologies Inc
KQ:189300
|
Korea | ₩230.19 Billion |
|
Hubei Kailong Chemical Group Co Ltd
SHE:002783
|
China | CN¥4.54 Billion |
|
Udemy Inc
NASDAQ:UDMY
|
USA | $407.24 Million |
|
New East New Materials Co Ltd
SHG:603110
|
China | CN¥101.55 Million |
|
Shore Bancshares Inc
NASDAQ:SHBI
|
USA | $5.67 Billion |
|
SI-TECH Information Technology Co Ltd
SHE:300608
|
China | CN¥921.06 Million |
|
Afya Ltd
NASDAQ:AFYA
|
USA | $4.40 Billion |
Liability Composition Analysis (2007–2024)
This chart breaks down Shandong Sinobioway Biomedicine Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Shandong Sinobioway Biomedicine Co Ltd stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shandong Sinobioway Biomedicine Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shandong Sinobioway Biomedicine Co Ltd (2007–2024)
The table below shows the annual total liabilities of Shandong Sinobioway Biomedicine Co Ltd from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥173.61 Million ≈ $25.40 Million |
+6.24% |
| 2023-12-31 | CN¥163.41 Million ≈ $23.91 Million |
-58.04% |
| 2022-12-31 | CN¥389.46 Million ≈ $56.99 Million |
+35.82% |
| 2021-12-31 | CN¥286.76 Million ≈ $41.96 Million |
+12.75% |
| 2020-12-31 | CN¥254.33 Million ≈ $37.22 Million |
-75.19% |
| 2019-12-31 | CN¥1.03 Billion ≈ $150.01 Million |
-30.42% |
| 2018-12-31 | CN¥1.47 Billion ≈ $215.60 Million |
+36.57% |
| 2017-12-31 | CN¥1.08 Billion ≈ $157.87 Million |
+573.61% |
| 2016-12-31 | CN¥160.16 Million ≈ $23.44 Million |
-41.10% |
| 2015-12-31 | CN¥271.92 Million ≈ $39.79 Million |
+1254.00% |
| 2014-12-31 | CN¥20.08 Million ≈ $2.94 Million |
-43.42% |
| 2013-12-31 | CN¥35.49 Million ≈ $5.19 Million |
+44.19% |
| 2012-12-31 | CN¥24.62 Million ≈ $3.60 Million |
+37.41% |
| 2011-12-31 | CN¥17.91 Million ≈ $2.62 Million |
-44.60% |
| 2010-12-31 | CN¥32.34 Million ≈ $4.73 Million |
-8.23% |
| 2009-12-31 | CN¥35.24 Million ≈ $5.16 Million |
+28.58% |
| 2008-12-31 | CN¥27.41 Million ≈ $4.01 Million |
+136.25% |
| 2007-12-31 | CN¥11.60 Million ≈ $1.70 Million |
-- |
About Shandong Sinobioway Biomedicine Co Ltd
Shandong Sinobioway Biomedicine Co., Ltd. engages in the pharmaceutical manufacturing industry in China. The company is involved in the chemical raw materials, chemical product manufacturing, and biopharmaceutical manufacturing; production and sales of medicines. It also offers operating chemical products, such as trimethyl ester and triethyl ester. The company was founded in 2000 and is based in… Read more